Joel S - Search Results

1

A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.

Philip PA, Joel S, Monkman SC, Dolega-Ossowski E, Tonkin K, Carmichael J, Idle JR, Harris AL. Philip PA, et al. Among authors: joel s. Br J Cancer. 1992 Feb;65(2):267-70. doi: 10.1038/bjc.1992.53. Br J Cancer. 1992. PMID: 1739628 Free PMC article. Clinical Trial.

2

Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.

Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL. Ord JJ, et al. Among authors: joel sp. Br J Cancer. 2005 Jun 20;92(12):2140-7. doi: 10.1038/sj.bjc.6602650. Br J Cancer. 2005. PMID: 15928663 Free PMC article. Clinical Trial.

3

Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.

Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL, Talbot DC. Braybrooke JP, et al. Among authors: joel s. Clin Cancer Res. 2003 Oct 15;9(13):4682-8. Clin Cancer Res. 2003. PMID: 14581337

4

Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors.

Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, Joel S, Donate F, Hayward C, Reich S, Middleton M, Mazar A, Harris AL. Lowndes SA, et al. Among authors: joel s. Clin Cancer Res. 2008 Nov 15;14(22):7526-34. doi: 10.1158/1078-0432.CCR-08-0315. Clin Cancer Res. 2008. PMID: 19010871 Clinical Trial.

5

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.

Levitt NC, Propper DJ, Madhusudan S, Braybrooke JP, Echeta C, Te Poele R, Davies SL, Flanagan E, Hickson ID, Joel S, Ganesan TS. Levitt NC, et al. Among authors: joel s. Br J Cancer. 2005 Jul 11;93(1):60-9. doi: 10.1038/sj.bjc.6602657. Br J Cancer. 2005. PMID: 15956976 Free PMC article. Clinical Trial.

6

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

Seymour MT, Patel N, Johnston A, Joel SP, Slevin ML. Seymour MT, et al. Among authors: joel sp. Br J Cancer. 1994 Oct;70(4):724-8. doi: 10.1038/bjc.1994.383. Br J Cancer. 1994. PMID: 7917928 Free PMC article. Clinical Trial.

7

The clinical pharmacology of etoposide: an update.

Joel S. Joel S. Cancer Treat Rev. 1996 May;22(3):179-221. doi: 10.1016/s0305-7372(96)90002-x. Cancer Treat Rev. 1996. PMID: 8841390 Review. No abstract available.

8

Etoposide dosage and pharmacodynamics.

Joel SP, Shah R, Slevin ML. Joel SP, et al. Cancer Chemother Pharmacol. 1994;34 Suppl:S69-75. doi: 10.1007/BF00684867. Cancer Chemother Pharmacol. 1994. PMID: 8070031 Review.

9

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.

Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PF. Harvey VJ, et al. Among authors: joel sp. Br J Cancer. 1985 Sep;52(3):363-7. doi: 10.1038/bjc.1985.202. Br J Cancer. 1985. PMID: 2994705 Free PMC article.

10

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.

Johnson PW, Joel SP, Love S, Butcher M, Pandian MR, Squires L, Wrigley PF, Slevin ML. Johnson PW, et al. Among authors: joel sp. Br J Cancer. 1993 Apr;67(4):760-6. doi: 10.1038/bjc.1993.138. Br J Cancer. 1993. PMID: 8385978 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters